Prospects for immunisation against Marburg and Ebola viruses.
about
Animal models for Ebola and Marburg virus infectionsEbola and Marburg hemorrhagic fevers: neglected tropical diseases?Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primatesEbola haemorrhagic feverParticulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogensAntibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccineAd35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus speciesEbola and Marburg virus vaccines."A time of fear": local, national, and international responses to a large Ebola outbreak in Uganda.Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirusThe Final (Oral Ebola) Vaccine Trial on Captive Chimpanzees?A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virusA nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.Infection control during filoviral hemorrhagic Fever outbreaks.The stem of vesicular stomatitis virus G can be replaced with the HIV-1 Env membrane-proximal external region without loss of G function or membrane-proximal external region antigenic properties.Transmission potential and design of adequate control measures for Marburg hemorrhagic feverVesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.Structures of protective antibodies reveal sites of vulnerability on Ebola virus.Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challengeMutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infectionEbola, the killer virus.Clinical aspects of Marburg hemorrhagic feverMice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virusEbolavirus and Haemorrhagic Syndrome.Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain.Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA.A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and FilovirusesProgress in filovirus vaccine development: evaluating the potential for clinical use.A single amino acid change resulting in loss of fluorescence of eGFP in a viral fusion protein confers fitness and growth advantage to the recombinant vesicular stomatitis virusFurther characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.Forty-five years of Marburg virus research.Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primatesVirus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges).
P2860
Q21131118-87CE4BE1-D88F-4543-8BF2-24621B9AFC02Q21558510-F211BE7B-EB30-4FE3-9436-1A759433B383Q21559476-F39D8384-1774-4324-B9E8-09383BF67E84Q24629338-1A15ECE9-13ED-4096-93F9-8B83BDD97E85Q27011190-C93ACF74-8B6F-4211-BA65-93684F7313F6Q27334697-72F8B4B0-06B7-4356-BC24-DCC2BAC09B83Q28485505-E3BB0E9C-2E5E-42E4-A1A2-36FACABA460CQ30234637-7D17EA92-93CB-4251-BAA2-B14C3F4BA22EQ30525722-AFA0E887-616D-4221-ABA3-A57FE56C5157Q30724121-A412C855-D93D-4B14-ADDD-583E5CF7CF7FQ30841328-A3D10A7D-6BFD-4A94-9A43-98C4C404760FQ34000122-221F257D-B4EA-41A2-86E4-7E6AFF417F4BQ34029668-D8F63D96-8BEE-4BCF-8686-D9DE5C2269A6Q34243483-5260A09D-D4F0-4EB6-928D-55935B9F5CEEQ34399656-D281680F-90A8-493A-8512-86CE270FA253Q34515978-79BA1AA3-C269-429D-9EEC-ED9099028F84Q34632946-5C903D19-527D-43EA-B289-8F96E9FEFFACQ34661120-21F008FB-B000-4B83-AF5A-32777E2CD808Q35076828-86BE3712-DCA4-481C-A60A-6EF9A275E73CQ35077419-D9FCAB87-CB83-484E-A219-5D58EF7374AEQ35275167-B7FD8CC4-5889-482C-9AA1-896DE68AD36DQ35300062-810CEB08-1E96-4302-AE84-0CC3474BFC08Q35300104-9BBF4D92-83C2-4B69-94C5-3C3D4ED25D18Q35368649-F841E694-51E2-429B-A7C8-9E44D497BF8BQ35446144-F84770DC-6655-4553-9546-C97DBEDF91D8Q35598223-D66D525B-F2FA-413B-BA9D-7D56BFE79331Q35670328-DCE08D65-2B4B-4B04-9EAB-BCCE7F2F8EE4Q35693152-2118A697-DC33-458B-9AB5-3FEAF5E182F2Q35772032-A7035F54-37AD-4CE9-8CFC-B4F88586C6D7Q35852525-B8447B34-3EC3-4B35-8503-A460B6157D65Q35980530-B6548327-1CDA-46D0-B66B-F46C863302B6Q36043269-9E9B0840-DC2C-4041-B5E0-C71D98C40F21Q36100545-F84AF223-2E62-4519-B8B1-FDDA5878CF67Q36177154-174D6442-DC00-409C-9510-E955AB9A0424Q36210186-4FF97B11-60D6-4DD0-8DA3-E76055B5A9C5Q36356863-C2ADB2EA-F5BA-48CC-AF16-2C3A9C3B401AQ36395831-05EFDF48-30C7-455E-A1C7-0C2DC8697302Q36522002-C12C41FC-14AA-4C4F-87FB-6C5AD0B03DFAQ36583281-BABB46B4-078E-4FBF-B8C4-47EC5D503D21Q36845999-FFCEB9BE-6A7E-4C06-9D79-376BE12E7F2A
P2860
Prospects for immunisation against Marburg and Ebola viruses.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Prospects for immunisation against Marburg and Ebola viruses.
@ast
Prospects for immunisation against Marburg and Ebola viruses.
@en
type
label
Prospects for immunisation against Marburg and Ebola viruses.
@ast
Prospects for immunisation against Marburg and Ebola viruses.
@en
prefLabel
Prospects for immunisation against Marburg and Ebola viruses.
@ast
Prospects for immunisation against Marburg and Ebola viruses.
@en
P2860
P356
P1476
Prospects for immunisation against Marburg and Ebola viruses.
@en
P2093
Daniel G Bausch
P2860
P304
P356
10.1002/RMV.661
P577
2010-11-01T00:00:00Z